Crestone, Inc.

Replidyne, Inc.

Aventis Pharmaceuticals Inc.

Joseph Guiles

Xicheng David Sun

Sarah A Strong

Nebojsa Janjic

Jian Qiu

Thale Jarvis

John C Rohloff

Raymond W Kosley, Jr

John G Jurcak

Albert Charles Gyorkos

Patrick Jimonet

Richard Lewis Jarvest

Stephen J Shimshock

Matthieu Barrague

Rosy Sher

John Michael Berge

Theodore M Tarasow

Xu-Yang Zhao

Catherine Simone Victoire Frydrych

Paul Justin Mueller

Jennifer Beall

Thale Cross Jarvis

The present invention provides novel heterocyclic urea compounds having useful antibacterial activity, pharmaceutical compositions comprising one or more of these compounds, methods of making the same, and methods of using the same.

Antibacteriall heterocyclic ureas

Novel bicyclic heteroaromatic compounds are provided that are inhibitors of bacterial methionyl tRNA synthetase (MetRS). Compounds of the invention generally have a left hand side phenylether constituent and a right hand side thienopyridone constituent. Also disclosed are methods for their preparation and their use in therapy as antibacterial agents, particularly as anti-agents.

Substituted phenylether-thienopyridone compounds with antibacterial activity

Methionyl tRNA synthetase inhibitors (MetRS) are provided for use in therapy as antibacterial agents inbased infection.

Methods and compounds for treatment of clostridium based infection

The present invention provides novel sulfone and sulfoxide substituted heterocyclic urea compounds having useful antibacterial activity. Use of these compounds as pharmaceutical compositions and methods of production are provided.

Antibacterial sulfone and sulfoxide substituted heterocyclic urea compounds

The present invention provides novel amide and sulfonamide substituted heterocyclic urea compounds having useful antibacterial activity. Use of these compounds as pharmaceutical compositions and method of their production are also provided.

Antibacterial amide and sulfonamide substituted heterocyclic urea compounds

Novel bicyclic heteroaromatic compounds are provided that are inhibitors of bacterial methionyl tRNA synthetase (MetRS). Compounds of the invention generally have a left hand side chroman group or left hand side tetrahydroquinoline group and a right hand side thienopyridone group. Also disclosed are methods for their preparation and their use in therapy as antibacterial agents, particularly as anti-agents.

Substituted thienopyridone compounds with antibacterial activity

Novel compounds in enantiomeric excess that are inhibitors of bacterial methionyl synthetase (MetRS) are disclosed. Also disclosed are methods for their preparation and their use in therapy as antibacterial agents, and in particular their use in therapy forinfection.

Enantiomeric compounds with antibacterial activity

A composition for binding FKBP proteins is disclosed, along with a method of treating conditions associated with neuronal degeneration, wherein said composition comprises a compound of formula I, wherein, R, R, R, Rand X are as defined herein.

N-sulfonylpipecolic acid derivative FKBP binding composition and pharmaceutical use thereof

Novel substituted thiophenes that are inhibitors of bacterial methionyl t-RNA synthetase (MRS) are disclosed. Also disclosed are method for their preparation and their use in therapy as anti-bacterial agents.

Growing community of inventors

Lafayette, CO, United States of America

Joseph Guiles